Basic Information
| Drug ID | DDPD01233 |
|
| Drug Name | Metoclopramide | |
| Molecular Weight | 299.796 | |
| Molecular Formula | C14H22ClN3O2 | |
| CAS Number | 364-62-5 | |
| SMILES | CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC | |
| External Links | ||
| DRUGBANK | DB01233 | |
| PubChem Compound | 4168 | |
| PDR | 2732 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.667 | - | 2.667 | - | https://onlinelibrary.wiley.com/doi/full/10.1002/jps.21276 |
| Boiling Point | 418.7 | ℃ | 418.7 | ℃ | https://www.lookchem.com/Metoclopramide-hydrochloride/ |
| Melting Point | 172.0 | ℃ | 171-173 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB4236007.aspx |
| pKa | 9.27 | - | 9.27 | - | https://pubchem.ncbi.nlm.nih.gov/compound/Metoclopramide |
| Log S | -3.18 | - | -3.18 | - | ADME Research, USCD |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 84.0 | % | 84 | % | PO, oral; | DRUGBANK | |
| AUC | 367.0 | ng.h/ml | 367.0 | ng.h/ml | inhalation, IH; | DRUGBANK | |
| Bioavailability | 40.7 | % | 40.7(30-100) | % | PO, oral; | DRUGBANK | Bioavailability | 47.0 | % | 47 | % | inhalation, IH; | DRUGBANK | Bioavailability | 76.0 | % | 76±38 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 41.0 | ng/ml | 41.0 | ng/ml | inhalation, IH; | DRUGBANK | C Max | 80.0 | ng/ml | 80.0 | ng/ml | Oral single dose; Elderly; | The Pharmacological Basis of Therapeutics | C Max | 18.0 | ng/ml | 18±6.2 | ng/ml | Oral single dose; Infants; | The Pharmacological Basis of Therapeutics |
| T Max | 1.3 | h | 1.25 | h | inhalation, IH; | DRUGBANK | T Max | 1.0 | h | ≤1 | h | Oral single dose; Elderly; | The Pharmacological Basis of Therapeutics | T Max | 2.5 | h | 2.5±0.7 | h | Oral single dose; Infants; | The Pharmacological Basis of Therapeutics |
| Clearance | 0.16 | L/h/kg | 0.16 | L/h/kg | Renal clearance; | DRUGBANK | Clearance | 0.70 | L/h/kg | 0.7 | L/h/kg | Total clearance; | RD, renal impairment, Renal disease，including uremia ↓ ; | DRUGBANK | Clearance | 0.50 | L/h/kg | 0.31-0.69 | L/h/kg | Total clearance; intravenous injection, IV; | DRUGBANK | Clearance | 0.37 | L/h/kg | 6.2±1.3 | ml/min/kg | Neonates ↑ ;Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.34 | L/h/kg | 5.7 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 3.5 | L/kg | 3.5 | L/kg | DRUGBANK | Volume of Distribution | 3.4 | L/kg | 3.4±1.3 | L/kg | Neonates ↑ ;Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 3.2 | L/kg | 3.2 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 5.5 | h | 5-6 | h | elimination half-life; normal renal function; | RD, renal impairment, Renal disease，including uremia ↑ ; | DRUGBANK | Half-life | 5.0 | h | 5.0±1.4 | h | RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;Age → ; | The Pharmacological Basis of Therapeutics | Half-life | 7.2 | h | 7.2 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 750.0 | mg/kg | 750.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | |
| Eliminate Route | 85.0 | % | 85 | % | Urinary excretion; PO, oral; | DRUGBANK | Eliminate Route | 20.0 | % | 20±9 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 30.0 | % | 30 | % | plasma proteins; | DRUGBANK | Protein Binding | 40.0 | % | 40±4 | % | RD, renal impairment, Renal disease，including uremia → ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 0.1 | mg/kg/dose | 0.1 | mg/kg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for neonates | 0.15 | mg/kg/dose | 0.15 | mg/kg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for neonates | 0.6 | mg/kg/day | 0.6 | mg/kg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for infants | 0.1 | mg/kg/dose | 0.1 | mg/kg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for infants | 0.2 | mg/kg/dose | 0.2 | mg/kg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for infants | 0.8 | mg/kg/day | 0.8 | mg/kg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 0.2 | mg/kg/dose | 0.2 | mg/kg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 0.2 | mg/kg/dose | 0.2 | mg/kg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 2.0 | mg/kg/dose | 2 | mg/kg/dose | intravenous infusion, iv in drop | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 10.0 | mg/dose | 10 | mg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 10.0 | mg/dose | 10 | mg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for children | 0.8 | mg/kg/day | 0.8 | mg/kg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 0.2 | mg/kg/dose | 0.2 | mg/kg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 0.2 | mg/kg/dose | 0.2 | mg/kg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 2.0 | mg/kg/dose | 2 | mg/kg/dose | intravenous infusion, iv in drop | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 10.0 | mg/dose | 10 | mg/dose | intravenous injection, IV | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 10.0 | mg/dose | 10 | mg/dose | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adolescents | 0.8 | mg/kg/day | 0.8 | mg/kg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adults | 60.0 | mg/day | 60 | mg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for adults | 20.0 | mg/dose | 20 | mg/dose | Metoclopramide Oral Solution | metoclopramide | PDR | |
| Max dose for geriatric | 60.0 | mg/day | 60 | mg/day | PO, oral | Metoclopramide Oral Solution | metoclopramide | PDR |
| Max dose for geriatric | 20.0 | mg/dose | 20 | mg/dose | Metoclopramide Oral Solution | metoclopramide | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1